Jcbd, LLC
$5.1M 10 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
ADC Therapeutics America, Inc.
ADC Therapeutics America, Inc. reported $5,093,955.33 across General Payments, Research, and Ownership to 4,269 physicians and teaching hospitals across 4,892 transactions.
- $5.1M Top quartile payer
- All-tracks total
- 4,892 Top quartile volume
- Transactions
- 4,269 Top quartile reach
- Recipients
- +$188.8K
- General Payments vs PY2023
ADC Therapeutics America, Inc. reported $5,093,955.33 across all CMS Open Payments tracks (General + Research + Ownership) to 4,269 physicians and teaching hospitals in Program Year 2024 - ranking #273 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $1,144,554.93, averaging $1.2K per recipient.
How ADC Therapeutics America, Inc.'s $5.1M all-tracks total breaks down
ADC Therapeutics America, Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
D
56/100
Total payments
D
57/100
Transaction volume
F
46/100
Physician reach
F
42/100
Payment type diversity
C
77/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer adc-therapeutics-america-inc ADC Therapeutics America, Inc.
$5.1M · #273/1,925 · 0.0% industry · PY2024
- TOT $5.1M
- RANK #273
- SHARE 0.0%
- TXN 4,892
- RCP 4,269
- CAT 6
- GEN $1.1M
- ΔGEN +$188.8K
- TOP1 3.6%
- PY 2024
Volume peers
Nearest volume peer: Jcbd, LLC ($5.1M)
ADC Therapeutics America, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
ADC Therapeutics America, Inc.'s CMS-reported General Payments increased by $188.8K (+19.8%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: ADC THERAPEUTICS AMERICA, INC.PY2023: ADC THERAPEUTICS AMERICA, INC.PY2024: ADC Therapeutics America, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $955,721.37
- PY2024
- $1,144,554.93
What the Data Shows for ADC Therapeutics America, Inc.
The all-tracks total above combines three CMS reporting categories - General Payments, Research Payments, and Ownership/Investment interests - not one undifferentiated figure. For ADC Therapeutics America, Inc., that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS publishes each Program Year's data roughly 12 months after the reporting period ends, so this reflects the most recently released cycle; see our methodology for how the tracks are standardized and compared across companies.
Of the 6 general-payment categories charted below, "Consulting Fee" is the largest at $559.9K across 98 transactions, 48.9% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
"Consulting Fee" leads ADC Therapeutics America, Inc.'s 6-category general-payment breakdown at $559.9K, 48.9% of the reported total.
ADC Therapeutics America, Inc. reports 6 general-payment categories - the top three are Consulting Fee (48.9%), Compensation for Services Other Than Consulting (19.2%), and Food and Beverage (10.9%). The remaining 3 categories make up 21.0% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How ADC Therapeutics America, Inc. divides its payments
Top payment categories by total reported dollar volume
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $559.9K | 98 | 48.9% |
| Compensation for Services Other Than Consulting | $219.7K | 63 | 19.2% |
| Food and Beverage | $124.9K | 3,791 | 10.9% |
| Travel and Lodging | $99.7K | 279 | 8.7% |
| Honoraria | $73.3K | 23 | 6.4% |
| Space Rental or Facility Fees | $67.1K | 15 | 5.9% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $153,893.41 (13.4%) of $1,144,554.93 in this company's General Payments records across 2,531 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for ADC Therapeutics America, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Cyrus Khan
$41,397.22 across 45 reported transactions
- 2
Adolfo Diaz Duque
$40,814.44 across 33 reported transactions
- 3
Emily Ayers
$26,758.89 across 18 reported transactions
- 4
Joshua Brody
$24,187.96 across 21 reported transactions
- 5
Michael Bishop
$20,734.90 across 18 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
ADC Therapeutics America, Inc. ranks #273 of 1,925 by total payments (top 14% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,678 of 1,838 by HHI (bottom 9% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Southern Anesthesia & Surgical, Inc (dba Ace Southern) : $3.8K total payments, HHI 112
- Actelion Pharmaceuticals US, Inc. : $5.0M total payments, HHI 112
- Array Biopharma Inc : $400.2K total payments, HHI 112
- Travere Therapeutics, Inc. : $2.0M total payments, HHI 112
- Avion Pharmaceuticals : $3.5K total payments, HHI 112
- Dompe US, Inc. : $1.3M total payments, HHI 111
- ADC Therapeutics America, Inc. (this company) : $1.1M total payments, HHI 111
- Kyowa Kirin, Inc. : $2.5M total payments, HHI 111
- Xeris Pharmaceuticals, Inc. : $1.2M total payments, HHI 110
- Mallinckrodt Hospital Products Inc. : $7.6M total payments, HHI 109
- Lexicon Pharmaceuticals, Inc. : $2.5M total payments, HHI 108
- Nevro Corp. : $2.5M total payments, HHI 107
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as ADC Therapeutics America, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about ADC Therapeutics America, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with ADC Therapeutics America, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
BrainScope Company, Inc.
$5.1M 25 recipients
Compare payment profiles
American Medical Technology Inc
$5.1M 0 recipients
Compare payment profiles
Pristine Surgical LLC
$5.1M 5 recipients
Compare payment profiles
SK Life Science, Inc.
$5.1M 20,538 recipients
Compare payment profiles
Spineart SA
$5.1M 233 recipients
Compare payment profiles
Put this to use
ADC Therapeutics America, Inc. ranks #273 of 1,925 by all-tracks total payments, led by "Consulting Fee".
- See where ADC Therapeutics America, Inc. sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Consulting Fee" spend across every manufacturer, not just ADC Therapeutics America, Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.